<clinical_study>
<study_id>
<org_name>
  VAHSRD
</org_name>
<org_full_name>
  Department of Veterans Affairs
</org_full_name>
<org_study_id>
  ADRD-018-98F
</org_study_id>
<nct_id>
  NCT00018200
</nct_id>
</study_id>
<is_fda_regulated>
  No
</is_fda_regulated>
<brief_title>
<textblock>
  Effect of Antidepressants on Back Pain
</textblock>
</brief_title>
<official_title>
<textblock>
  Efficacy of Antidepressants in Chronic Back Pain
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Department of Veterans Affairs
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Atkinson, Joseph - Principal Investigator
</name_title>
<organization>
  Department of Veterans Affairs
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Federal Government
</regulatory_authority>
<has_dmc>
  Yes
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
The  purpose  of  this  study  is  to  determine  whether  different  types  of  antidepressant  medicines  relieve  back  pain  that  has  lasted  at  least  six  months  on  a  daily  basis.  Study  participants  will  be  assigned  to  treatment  with  either  a  antidepressant  acting  on  the  serotonin  system  in  the  brain  (fluoxetine),  one  acting  on  the  noradrenaline system  (desipramine,  or  to  a  control  medication  not  expected  to  relieve  pain  (benztropine).  Each  participant  will  be  seen  at  least  nine  times  during  their  12  weeks  on  medication.  This  is  a  phase  2/3,  outpatient  study.  
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2010-05 
</date>
</status_block>
<start_date>
<date>
  1999-04
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2004-03
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2003-12
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 2
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
</design>
<design>
  Placebo Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Efficacy Study
</design>
<number_of_arms>
  3
</number_of_arms>
<primary_outcome>
<measure>
  Descriptor Differential Scale Pain Intensity
</measure>
<time_frame>
  12 weeks post baseline
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<enrollment
 type="Actual"
>
  130
</enrollment>
<condition>
  Back Pain
</condition>
<condition>
  Sciatica
</condition>
<arm_group>
<arm_group_label>
  1
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Desipramine, low, middle or high exposure
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  2
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Fluoxetine, low, middle, or high exposure
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  3
</arm_group_label>
<arm_type>
  Placebo Comparator
</arm_type>
<description>
<textblock>
  Benztropine .125-.5mg daily
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Desipramine
</primary_name>
<description>
<textblock>
  Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<other_name>
  Anafranil
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Fluoxetine
</primary_name>
<description>
<textblock>
  Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
</textblock>
</description>
<arm_group_label>
  2
</arm_group_label>
<other_name>
  Prozac
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Benztropine
</primary_name>
<description>
<textblock>
  Daily dose 0.125 to 0.5mg
</textblock>
</description>
<arm_group_label>
  3
</arm_group_label>
<other_name>
  Cogentin
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria: 
    - Chronic back pain (pain on a daily basis for  six months or longer)
 
    -  Age 18-65
 
    -  No major medical illness
 
  Exclusion Criteria:
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  65 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Principal Investigator
</role>
<name>
  Joseph H. Atkinson, MD
</name>
<affiliation>
<agency>
  VA San Diego Healthcare System, San Diego
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Judy Ortega, BA
</name>
<phone>
  (858) 642-3830
</phone>
<phone_ext>
</phone_ext>
<email>
  judith.ortega@va.gov
</email>
</contact>
<contact>
<name>
  Shetal Patel, PhD
</name>
<phone>
  (858) 642-3830
</phone>
<phone_ext>
</phone_ext>
<email>
  backpainresearch@vapop.ucsd.edu
</email>
</contact>
<location>
<facility>
<name>
  VA San Diego Healthcare System, San Diego
</name>
<address>
<city>
  San Diego
</city>
<state>
  California
</state>
<zip>
  92161
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Robert M Smith, MD BS
</name>
<phone>
  858-642-3657
</phone>
<phone_ext>
</phone_ext>
<email>
  robert.smith2@va.gov
</email>
</contact>
<contact>
<name>
  Janet M Peyton, MA MA
</name>
<phone>
  (858) 642-3657
</phone>
<phone_ext>
</phone_ext>
<email>
  janet.peyton@va.gov
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Joseph H. Atkinson, MD
</name>
</contact>
</location>
<keyword>
  analgesia
</keyword>
<keyword>
  Back pain
</keyword>
<keyword>
  sciatica
</keyword>
<initial_release_date>
  2001-07-03
</initial_release_date>
<last_release_date>
2010-05-20 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
